D
Regeneron Pharmaceuticals, Inc. REGN
$687.86 $0.710.10%
Recommendation
Sell
Prev Close
$687.15
Volume
152,847
Avg Vol (90D)
881,482
Market Cap
$73.54B
Dividend & Yield
$0.88(0.13%)
52-Week Range
$642.00 - $1,211.20
P/E (TTM)
17.95
EPS (TTM)
$38.29
My Lists My Alerts
Rating
Reward
C
Fair
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Excellent
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
2/27/2025 - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
3/6/2025 - PR Newswire
Interesting REGN Put And Call Options For April 25th
3/6/2025 - Stock Options Channel
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Aigen Investment Management LP's 8th Largest Position
3/6/2025 - MarketBeat
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of ...
3/6/2025 - GuruFocus
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
3/6/2025 - PR Newswire
US Bancorp DE Acquires 1,078 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
3/6/2025 - MarketBeat
Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your ...
3/6/2025 - GuruFocus
Deadline Alert: Regeneron Pharmaceuticals, Inc. ...
3/5/2025 - GuruFocus
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
3/5/2025 - PR Newswire
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: ...
3/5/2025 - GuruFocus
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025
3/5/2025 - PR Newswire
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Fisher Asset Management LLC
3/5/2025 - Ticker Report
Seizert Capital Partners LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
3/5/2025 - MarketBeat
Assetmark Inc. Sells 3,005 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
3/5/2025 - MarketBeat
Private Trust Co. NA Sells 77 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
3/5/2025 - Ticker Report
Schechter Investment Advisors LLC Sells 117 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
3/5/2025 - Ticker Report
SBI Securities Co. Ltd. Invests $464,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
3/5/2025 - MarketBeat
REGN DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. ...
3/4/2025 - GuruFocus
Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 45th Annual Health Care Conference (Transcript)
3/4/2025 - SeekingAlpha
Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 45th Annual Health Care Conference (Transcript)
3/4/2025 - Seeking Alpha: Transcripts
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead ...
3/4/2025 - GuruFocus
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi ...
3/4/2025 - GuruFocus
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
3/4/2025 - PR Newswire
Biogen Stock Is Mutating Into a Value Play
2/20/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$14.20B
EBITDA (TTM)
$4.60B
EBIT (TTM)
$4.12B
Net Income (TTM)
$4.41B
Balance Sheet
Total Assets (Q)
$37.76B
Total Debt (Q)
$2.94B
Total Liabilities (Q)
$8.41B
Book Value Per Share (Q)
$273.57
Cash Flow
Cash from Operations (TTM)
$4.42B
Cash from Investing (TTM)
-$2.47B
Cash from Financing (TTM)
-$2.20B
Net Change in Cash (TTM)
-$248.80M
Filings
Filing Date
Wednesday, February 5, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
0.74
7-Day Total Return
-4.92%
30-Day Total Return
1.15%
60-Day Total Return
-10.44%
90-Day Total Return
-26.97%
Year to Date Total Return
-3.83%
1-Year Total Return
-29.28%
2-Year Total Return
-11.87%
3-Year Total Return
11.21%
5-Year Total Return
39.17%
52-week Low
Feb 04, 2025 - $642.00
52-week High
Aug 27, 2024 - $1,211.20
Valuation
Market Cap
$73.54B - Large Cap
Enterprise Value
$58.57B
Price/Sales (TTM)
5.51
Price/Book (Q)
2.51
Dividends and Shares
Shares Outstanding
113.80M
Dividend Per Share (Most Recent)
$0.88
Dividend Per Share (TTM)
$0.88
Corporate Info
Website
www.regeneron.com
Phone Number
914 847 7000
Address
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Country
United States
Year Founded
1988
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to... more
NASDAQ 03/06/2025 11:52AM Eastern Quotes delayed
Weiss Ratings